February 7, 2024

Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy

The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
January 24, 2024

New Findings on Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) is a rare, progressive, and often fatal genetic disease caused by mutations in the transthyretin (TTR) gene. It results in the accumulation of amyloid fibrils in the nerves, heart, and other organs, leading to symptoms such as polyneuropathy and cardiomyopathy, as well as other serious complications.
January 22, 2024

Pluvicto: Most Asked Questions

"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
January 19, 2024

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
December 16, 2023

Navigating Complex Moral Choices in Obstetrics: The Intersection of Maternal Cancer and Pregnancy

During her rotation in obstetrics and gynecology, a resident encountered a 28-year-old pregnant woman at 13 weeks gestational age, who already has three healthy children. I […]
PROMACTA® (eltrombopag) – Treating Severe Aplastic Anemia: Evidence and FAQs
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more